ResMed Inc. (RMD) has shown
strong traction in the bio-tech market off late, with significant interest evidenced by various investment firms and stock holders. Some key players like
abrdn plc and Mediolanum International Funds Ltd have adjusted their holdings in ResMed, while others like
Jericho Financial LLP and Chicago Partners Investment Group LLC made new investments. Despite some steps down in its
organic sales growth, RMD is benefited from 'mega trends' and has consistently surpassed earnings and revenue estimates in its recent quarters, as indicated by its Q1 and Q2 2025 earnings call highlights. Analysts have issued upgrades for RMD, anticipating its stock price to rise. However, there have been cases of insider selling, hinting at possible hesitancy. Furthermore, it faces threats from competitors like
Eli Lilly, whose obesity drugs pose a potential market challenge to
ResMed's sleep apnea devices. Despite some stock downturns, ResMed’s strong financial performance and its
investment efficiency continue driving the stock’s rally. Lastly, ResMed's push for innovation can be seen in its launch of the first fabric mask, aimed to improve
CPAP therapy and overall sleep health.
Resmed RMD News Analytics from Mon, 24 Jun 2024 07:00:00 GMT to Sat, 08 Feb 2025 08:25:09 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor -3
